

28 June 2024

Notice under ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547

PharmAust Limited (ABN 35 094 006 023) (ASX: PAA) (**Company**) is proposing to conduct a share purchase plan (**SPP**) as part of its capital raising initiative announced by the Company on 21 June 2024. Under the SPP, eligible shareholders may apply to purchase up to A\$30,000 worth of fully paid ordinary shares in the Company (**SPP Shares**) at an offer price of \$0.19 per SPP Share, being the price paid by institutional investors under the institutional placement announced by the Company on 21 June 2024.

Under ASIC Corporations (Share and Interest Purchase Plans) Instrument 2019/547 (**ASIC Instrument 2019/547**), the Company gives notice that:

- (a) the Company will make offers to issue SPP Shares under the SPP without disclosure to investors under Part 6D.2 of the *Corporations Act 2001* (Cth) (**Corporations Act**);
- (b) this notice is being given under paragraph 7(f)(ii) of ASIC Instrument 2019/547, which requires the Company to give this notice to ASX within 24 hours before the SPP offer is made;
- (c) as at the date of this notice, the Company has complied with:
 - (i) the provisions of Chapter 2M of the *Corporations Act* as they apply to the Company; and
 - (ii) sections 674 and 674A of the *Corporations Act*; and
- (d) as at the date of this notice, there is no “excluded information” of the type referred to in sections 708A(7) and 708A(8) of the *Corporations Act* that is required to be set out in this notice (as if this notice were a notice under section 708A(5)(e) of the *Corporations Act*).

-Ends-

This announcement is authorised for release by the Board of Directors of PharmAust Limited.

For further information, please contact:

Dr Michael Thurn
Managing Director
investorenquiries@pharmaust.com

P +61 (3) 9692 7222
W www.pharmaust.com

Media:
Catherine Strong
Morrow Sodali
c.strong@morrrowsodali.com
0406 759 268

About PharmAust Limited:

PharmAust Limited is listed on the Australian Securities Exchange (ASX Code: PAA). PAA is a clinical-stage biotechnology company developing therapeutics for neurodegenerative diseases. The company is focused on repurposing monepantel (MPL) for amyotrophic lateral sclerosis (ALS). ALS is the most common form of motor neurone disease (MND) and affects both upper and lower motor neurons.

MPL is a potent and safe inhibitor of the mTOR pathway. This pathway plays a central role in the growth and proliferation of cancer cells and degenerating neurons. The mTOR pathway regulates the cellular “cleaning process”, where toxic proteins are broken down into macromolecules to be reused. This autophagic process is disrupted in most neurodegenerative diseases, including ALS.

The company recently announced positive top-line results for its Phase 1 MEND study in participants with ALS. PAA is in the planning stages for a registration adaptive Phase 2/3 STRIKE clinical study and anticipates commencing enrolment in H2 CY 2024. This single pivotal study could potentially lead to accelerated approval with the US Food and Drug Administration for monepantel for the treatment of ALS in 2026.

In 2024, the Neurodegenerative Disease Market size is estimated to be worth USD 55.12 billion, with a forecast growth (CAGR) of 7.14% the market size is expected to reach USD 77.82 billion by 2029.¹

¹ <https://www.mordorintelligence.com/industry-reports/neurodegenerative-disease-market>

PharmAust Investor Hub:

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning PharmAust. This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

Access the investor hub by scanning the QR code or visiting: <https://investorhub.pharmaust.com/>

